PE10299A1 - Procedimiento para sintetizar piridinas sustituidas - Google Patents

Procedimiento para sintetizar piridinas sustituidas

Info

Publication number
PE10299A1
PE10299A1 PE1997001004A PE00100497A PE10299A1 PE 10299 A1 PE10299 A1 PE 10299A1 PE 1997001004 A PE1997001004 A PE 1997001004A PE 00100497 A PE00100497 A PE 00100497A PE 10299 A1 PE10299 A1 PE 10299A1
Authority
PE
Peru
Prior art keywords
compound
formula
base
procedure
pyridin
Prior art date
Application number
PE1997001004A
Other languages
English (en)
Spanish (es)
Inventor
Robert Lee Dow
Keith Michael Devries
Stephen Wayne Wright
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE10299A1 publication Critical patent/PE10299A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/73Unsubstituted amino or imino radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
PE1997001004A 1996-11-14 1997-11-11 Procedimiento para sintetizar piridinas sustituidas PE10299A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3088096P 1996-11-14 1996-11-14

Publications (1)

Publication Number Publication Date
PE10299A1 true PE10299A1 (es) 1999-02-10

Family

ID=21856496

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1997001004A PE10299A1 (es) 1996-11-14 1997-11-11 Procedimiento para sintetizar piridinas sustituidas

Country Status (32)

Country Link
US (1) US6291489B1 (US06291489-20010918-C00048.png)
EP (1) EP0938476B1 (US06291489-20010918-C00048.png)
JP (1) JP3510635B2 (US06291489-20010918-C00048.png)
KR (1) KR20000053314A (US06291489-20010918-C00048.png)
CN (1) CN1237160A (US06291489-20010918-C00048.png)
AP (1) AP805A (US06291489-20010918-C00048.png)
AR (1) AR010584A1 (US06291489-20010918-C00048.png)
AT (1) ATE319687T1 (US06291489-20010918-C00048.png)
AU (1) AU4634697A (US06291489-20010918-C00048.png)
BG (1) BG103393A (US06291489-20010918-C00048.png)
BR (1) BR9712951A (US06291489-20010918-C00048.png)
CA (1) CA2270386C (US06291489-20010918-C00048.png)
CO (1) CO4930261A1 (US06291489-20010918-C00048.png)
DE (1) DE69735433D1 (US06291489-20010918-C00048.png)
EA (1) EA199900375A1 (US06291489-20010918-C00048.png)
GT (1) GT199700118A (US06291489-20010918-C00048.png)
HR (1) HRP970612A2 (US06291489-20010918-C00048.png)
ID (1) ID18898A (US06291489-20010918-C00048.png)
IL (1) IL129688A0 (US06291489-20010918-C00048.png)
IS (1) IS5029A (US06291489-20010918-C00048.png)
MA (1) MA24401A1 (US06291489-20010918-C00048.png)
MY (1) MY132507A (US06291489-20010918-C00048.png)
NO (1) NO992296L (US06291489-20010918-C00048.png)
OA (1) OA11044A (US06291489-20010918-C00048.png)
PA (1) PA8441401A1 (US06291489-20010918-C00048.png)
PE (1) PE10299A1 (US06291489-20010918-C00048.png)
TN (1) TNSN97172A1 (US06291489-20010918-C00048.png)
TR (1) TR199901063T2 (US06291489-20010918-C00048.png)
UY (1) UY24774A1 (US06291489-20010918-C00048.png)
WO (1) WO1998021184A1 (US06291489-20010918-C00048.png)
YU (1) YU22099A (US06291489-20010918-C00048.png)
ZA (1) ZA9710186B (US06291489-20010918-C00048.png)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002511460A (ja) * 1998-04-08 2002-04-16 ノバルティス アクチエンゲゼルシャフト 新規除草剤
US6090942A (en) * 1998-10-15 2000-07-18 Pfizer Inc. Process and intermediates for a β3 -adrenergic receptor agonist
US6515134B1 (en) * 1999-02-16 2003-02-04 Kaneka Corporation Substituted acetylpridine derivatives and process for the preparation of intermediates for optically active beta-3 agonist by the use of the same
US6455734B1 (en) 2000-08-09 2002-09-24 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
ATE280167T1 (de) * 1999-07-23 2004-11-15 Pfizer Prod Inc Zwischenprodukte und ein verfahren zur herstellung von beta3-adrenergischer rezeptor- agoniste
JPWO2003033468A1 (ja) * 2001-10-17 2005-02-03 株式会社カネカ (S)−α−ハロメチルピリジンメタノール誘導体の製造方法
AU2003248352A1 (en) 2002-02-27 2003-09-09 Pfizer Products Inc. PROCESSES AND INTERMEDIATES USEFUL IN PREPARING Beta3-ADRENERGIC RECEPTOR AGONISTS
AU2003209527A1 (en) * 2002-02-27 2003-09-09 Pfizer Products Inc. Crystal forms of (r)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol
US6864268B2 (en) 2002-02-27 2005-03-08 Pfizer Inc. β3 adrenergic receptor agonists
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
KR100751163B1 (ko) 2003-05-09 2007-08-22 에프. 호프만-라 로슈 아게 알파-1 아드레날린 작용물질로서의 메틸 인돌 및 메틸피롤로피리딘
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
JP5791500B2 (ja) 2008-05-23 2015-10-07 パンミラ ファーマシューティカルズ,エルエルシー. 5−リポキシゲナーゼ活性化タンパク質阻害剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4358455A (en) 1980-12-23 1982-11-09 Merck & Co., Inc. Aralkylamindethanol heterocyclic compounds
US5019578A (en) 1987-11-27 1991-05-28 Merck & Co., Inc. β-adrenergic agonists
NZ265692A (en) 1993-06-14 1997-02-24 Pfizer Indole- and benzofuran- containing hydroxyamines and analogs; pharmaceutical compositions
IL113410A (en) 1994-04-26 1999-11-30 Merck & Co Inc Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them
JPH11504648A (ja) 1995-05-10 1999-04-27 ファイザー・インコーポレーテッド β−アドレナリン作動性アゴニスト
EP0824519A1 (en) 1995-05-10 1998-02-25 Pfizer Inc. Beta-adrenergic agonists

Also Published As

Publication number Publication date
UY24774A1 (es) 1998-05-05
MY132507A (en) 2007-10-31
ID18898A (id) 1998-05-20
ATE319687T1 (de) 2006-03-15
JP2000504347A (ja) 2000-04-11
ZA9710186B (en) 1999-05-12
DE69735433D1 (de) 2006-05-04
AR010584A1 (es) 2000-06-28
IL129688A0 (en) 2000-02-29
MA24401A1 (fr) 1998-07-01
WO1998021184A1 (en) 1998-05-22
AU4634697A (en) 1998-06-03
KR20000053314A (ko) 2000-08-25
OA11044A (en) 2002-02-20
TNSN97172A1 (fr) 2005-03-15
AP805A (en) 2000-01-28
NO992296D0 (no) 1999-05-12
TR199901063T2 (xx) 1999-08-23
IS5029A (is) 1999-04-16
CA2270386A1 (en) 1998-05-22
NO992296L (no) 1999-05-12
PA8441401A1 (es) 2000-05-24
CO4930261A1 (es) 2000-06-27
EP0938476B1 (en) 2006-03-08
YU22099A (sh) 2001-09-28
HRP970612A2 (en) 1998-08-31
BG103393A (en) 2000-07-31
EP0938476A1 (en) 1999-09-01
CA2270386C (en) 2004-08-03
AP9701147A0 (en) 1998-01-31
BR9712951A (pt) 1999-12-07
CN1237160A (zh) 1999-12-01
US6291489B1 (en) 2001-09-18
EA199900375A1 (ru) 1999-12-29
JP3510635B2 (ja) 2004-03-29
GT199700118A (es) 1999-05-05

Similar Documents

Publication Publication Date Title
PE10299A1 (es) Procedimiento para sintetizar piridinas sustituidas
DK1445258T3 (da) Aktivator for peroxisomproliferator-aktiveret receptor delta
CO4990955A1 (es) Derivados de n-alcanoilofenilalanina
PE20020753A1 (es) Heteroaromaticos fusionados como activadores de la glucoquinasa
KR920700202A (ko) 아크릴로일 치환된 피롤 유도체
PE20001483A1 (es) Acidos oxamicos y derivados como ligandos de receptores tiroideos
RU2009141612A (ru) Способ получения амидного соединения
CO4990936A1 (es) Derivados de n-aroilfenilalanina
PE20021072A1 (es) DERIVADOS DE DIHIDRO-BENZO(b) (1,4)-DIAZEPIN-2-ONA COMO ANTAGONISTAS I DE mGLUR2
TR199801868T2 (xx) 1,2,3,4-tetrahidronaftalin t�revleri yerine e�de�erinin kullan�lmas�.
PE20070007A1 (es) Metodos para sintetizar derivados de 6-alquilaminoquinolina
PE20040672A1 (es) Derivados de fenil o heteroaril amino alcano
KR960702460A (ko) 티아졸리딘디온 및 이것을 함유하는 약제(new thiazolidindiones and drugs containing them)
CY1106677T1 (el) Παρασκευη ν1-(2’-πυριδυλ)-1, 2-προπανοδιαμινο σουλφαμικου οξεος και χρηση αυτου στη συνθεση βιολογικως δραστικων πιπεραζινων
CA2444244A1 (en) Methods of synthesizing acylanilides including bicalutamide and derivatives thereof
PE20040520A1 (es) Derivados de n-acilamino bencil eter
KR950701321A (ko) 신규의 치환된 3급 아미노 화합물의 또는 이의 염(Novel substituted tertiary amino compound or salt thereof)
DE60007745D1 (de) Heterocyclische aminopyrrolidon-derivate als melatonergene wirkstoffe
PE20010954A1 (es) Bencimidazoles, su preparacion y su empleo como medicamentos
KR940005540A (ko) 카르복시산 유도체
PE20000725A1 (es) Compuestos de alcoxipirrolidinona como inhibidores de proteasas
NZ503916A (en) Method of synthesis of pyrrole and indole amides
JPS5687568A (en) Imidazoline compound
EA200100783A1 (ru) Соединения - агонисты дофаминовых рецепторов d1
KR850008167A (ko) 4(3h)-퀴나졸리논의 제조방법

Legal Events

Date Code Title Description
FA Abandonment or withdrawal